Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Akebia Therapeutics will report Q1 2026 results before the market opens on May 7, 2026; analysts expect ($0.01) EPS and about $51.67 million in revenue, with the earnings call at 8:00 AM ET.
• In the prior quarter Akebia missed EPS (reported ($0.05) vs. consensus ($0.03)) but beat revenue at $57.62 million, and the company remains unprofitable with analysts projecting $0 EPS for the current and next fiscal year.
• CEO John P. Butler bought 69,270 shares in March at $1.25 (increasing his stake ~2.1%), while Wall Street's consensus rating is currently Hold with an average target price of $4.67.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $51.6670 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.02). The company had revenue of $57.62 million during the quarter, compared to the consensus estimate of $48.37 million. Akebia Therapeutics had a negative net margin of 2.26% and a negative return on equity of 16.70%. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Price Performance

Shares of Akebia Therapeutics stock traded up $0.07 during midday trading on Wednesday, reaching $1.52. The company had a trading volume of 936,237 shares, compared to its average volume of 2,948,240. The stock has a fifty day simple moving average of $1.38 and a 200 day simple moving average of $1.60. The company has a current ratio of 1.55, a quick ratio of 1.46 and a debt-to-equity ratio of 1.48. Akebia Therapeutics has a 1-year low of $1.14 and a 1-year high of $4.08. The company has a market capitalization of $406.40 million, a price-to-earnings ratio of -75.71 and a beta of 0.35.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AKBA. Wall Street Zen lowered shares of Akebia Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. BTIG Research restated a "buy" rating and issued a $4.00 price target on shares of Akebia Therapeutics in a report on Tuesday, April 7th. Zacks Research raised shares of Akebia Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 7th. Piper Sandler lowered their price objective on shares of Akebia Therapeutics from $6.00 to $4.00 and set an "overweight" rating on the stock in a research report on Friday, February 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $6.00 price target on shares of Akebia Therapeutics in a report on Friday, February 6th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $4.67.

Insider Buying and Selling at Akebia Therapeutics

In other Akebia Therapeutics news, CEO John P. Butler bought 69,270 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The stock was purchased at an average cost of $1.25 per share, with a total value of $86,587.50. Following the completion of the acquisition, the chief executive officer owned 3,367,064 shares in the company, valued at $4,208,830. This trade represents a 2.10% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Cibc World Markets Corp purchased a new position in Akebia Therapeutics during the fourth quarter worth $27,000. Brevan Howard Capital Management LP purchased a new position in Akebia Therapeutics during the second quarter worth $62,000. Polymer Capital Management US LLC boosted its stake in shares of Akebia Therapeutics by 49.5% during the third quarter. Polymer Capital Management US LLC now owns 18,232 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 6,034 shares during the period. Baird Financial Group Inc. boosted its stake in shares of Akebia Therapeutics by 23.0% during the first quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 4,000 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Akebia Therapeutics by 263.0% in the second quarter. Tower Research Capital LLC TRC now owns 22,822 shares of the biopharmaceutical company's stock valued at $83,000 after acquiring an additional 16,535 shares in the last quarter. 33.92% of the stock is owned by hedge funds and other institutional investors.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company's lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia's research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.